POSTRADIATION METABOLIC TUMOR VOLUME PREDICTS OUTCOME IN HEAD-AND-NECK CANCER

被引：55
作者：
Murphy, James D.
La, Trang H.
Chu, Karen
Quon, Andrew [2 ]
Fischbein, Nancy J. [3 ]
Maxim, Peter G.
Graves, Edward E.
Loo, Billy W., Jr.
Le, Quynh-Thu [1 ]
机构：
[1] Stanford Univ, Ctr Canc, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Nucl Med, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 80卷 / 02期
关键词：
Head-and-neck cancer; Positron emission tomography; Metabolic tumor volume; POSITRON-EMISSION-TOMOGRAPHY; SQUAMOUS-CELL CARCINOMA; COMPUTED-TOMOGRAPHY; RADIATION-THERAPY; FDG-PET; RECURRENT; RADIOTHERAPY; PATHOGENESIS; MANAGEMENT; IMPACT;
D O I：
10.1016/j.ijrobp.2010.01.057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: To explore the prognostic value of metabolic tumor volume measured on postradiation F-18-fluorodeoxyglucose positron emission tomography (PET) imaging in patients with head-and-neck cancer. Methods and Materials: Forty-seven patients with head-and-neck cancer who received pretreatment and post-treatment PET/computed tomography (CT) imaging along with definitive chemoradiotherapy were included in this study. The PET/CT parameters evaluated include the maximum standardized uptake value, metabolic tumor volume (MTV2.0-MTV4.0; where MTV2.0 refers to the volume above a standardized uptake value threshold of 2.0), and integrated tumor volume. Kaplan-Meier and Cox regression models were used to test for association between PET endpoints and disease-free survival and overall survival. Results: Multiple postradiation PET endpoints correlated significantly with outcome; however, the most robust predictor of disease progression and death was MTV2.0. An increase in MTV2.0 of 21cm(3) (difference between 75th and 25th percentiles) was associated with an increased risk of disease progression (hazard ratio [HR] = 2.5, p = 0.0001) and death (HR = 2.0, p = 0.003). In patients with nonnasopharyngeal carcinoma histology (n = 34), MTV2.0 <18 cm(3) and MTV2.0 >= 18 cm(3) yielded 2-year disease-free survival rates of 100% and 63%, respectively (p = 0.006) and 2-year overall survival rates of 100% and 81%, respectively (p = 0.009). There was no correlation between MTV2.0 and disease-free survival or overall survival with nasopharyngeal carcinoma histology (n = 13). On multivariate analysis, only postradiation MTV2.0 was predictive of disease-free survival (HR = 2.47, p = 0.0001) and overall survival (HR = 1.98,p = 0.003). Conclusions: Postradiation metabolic tumor volume is an adverse prognostic factor in head-and-neck cancer. Biomarkers such as MTV are important for risk stratification and will be valuable in the future with risk-adapted therapies. (C) 2011 Elsevier Inc.
引用
收藏
页码：514 / 521
页数：8
相关论文
共 25 条
[1]   Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose [J].
Allal, AS ;
Slosman, DO ;
Kebdani, T ;
Allaoua, M ;
Lehmann, W ;
Dulguerov, P .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05) :1295-1300
[2]   Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy [J].
Allal, AS ;
Dulguerov, P ;
Allaoua, M ;
Haenggeli, CA ;
El Ghazi, EA ;
Lehmann, W ;
Slosman, DO .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1398-1404
[3]   Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers [J].
Andrade, Regiane S. ;
Heron, Dwight E. ;
Degirmenci, Berna ;
Filho, Pedro A. A. ;
Branstetter, Barton F. ;
Seethala, Raja R. ;
Ferris, Robert L. ;
Avril, Norbert .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (05) :1315-1322
[4]   A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck [J].
Budach, W ;
Hehr, T ;
Budach, V ;
Belka, C ;
Dietz, K .
BMC CANCER, 2006, 6 (1)
[5]   Pathogenesis and treatment of nasopharyngeal carcinoma [J].
Chan, ATC ;
Teo, PML ;
Huang, DP .
SEMINARS IN ONCOLOGY, 2004, 31 (06) :794-801
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy [J].
Ford, Eric C. ;
Herman, Joseph ;
Yorke, Ellen ;
Wahl, Richard L. .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (10) :1655-1665
[8]   Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment [J].
Goerres, GW ;
von Schulthess, GK ;
Hany, TF .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2002, 179 (05) :1337-1343
[9]   Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer [J].
Gourin, CG ;
Williams, HT ;
Seabolt, WN ;
Herdman, AV ;
Howington, JW ;
Terris, DJ .
LARYNGOSCOPE, 2006, 116 (05) :705-710
[10]   Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer [J].
Greven, KM ;
Williams, DW ;
McGuirt, WF ;
Harkness, BA ;
D'Agostino, RB ;
Keyes, JW ;
Watson, NE .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2001, 23 (11) :942-946
123